Redox status of plasma homocysteine and other plasma thiols in stroke patients


      Despite the growing evidence that plasma homocysteine is a cardiovascular risk factor, the mechanism behind the vascular injuries is still unknown. Studies are difficult as a result of the fact that little is known about the formation of different homocysteine species in vivo. Since extracellular glutathione and cysteine may influence the formation of different homocysteine species, we have in the present study investigated the different fractions of homocysteine and their relation to the different fractions of glutathione and cysteine in stroke patients and control subjects. We found a ratio of about 32–33% between reduced and total plasma glutathione concentrations and 2.6–3.0% between reduced and total plasma cysteine concentrations both in patients and in healthy control subjects. We noted an elevated concentration of total plasma homocysteine in stroke patients, but no difference in the ratio between reduced and total plasma homocysteine concentrations in patients and control subjects (mean value 1.20 and 1.10%, respectively). However, in a subgroup of patients with higher concentrations of total plasma homocysteine, we observed a significantly lower ratio of reduced to total plasma homocysteine compared to a subgroup of patients with lower concentration of total plasma homocysteine. A low reduced/total ratio of plasma homocysteine in combination with elevated plasma homocysteine concentrations might reflect an increased pro-oxidant activity in plasma from these patients. Thus, increased pro-oxidant activity in plasma might be one factor, besides genetic and nutritional factors, that could explain hyperhomocysteinemia. Since substantial evidence indicates that progression of atherosclerosis is related to enhanced pro-oxidant activity, the premature vascular disease associated with increased plasma homocysteine concentration might be as a result of increased pro-oxidant activity and the elevated plasma homocysteine concentration may only reflect the increased oxidative stress.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mudd S.H
        • Levy H.L
        • Skovby F
        Disorders of transsulfuration.
        in: Scriver C.G Beaudet A.L Sly W.S Valle D The Metabolic Basis of Inherited Disease. 6th ed. McGraw-Hill, New York1989: 693-734
        • Brattström L
        • Hardebo J
        • Hultberg B
        Moderate homocysteinemia — a possible risk factor for arteriosclerotic cerebrovascular disease.
        Stroke. 1984; 15: 1012-1016
        • Boers G.H.J
        • Smals A.G.H
        • Trijbels F.J.M
        • Fowler B
        • Bakkeren J.A.J.M
        • Schoonderwaldt H.C
        • Kleijer W.J
        • Kloppenborg P.W.C
        Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease.
        N. Engl. J. Med. 1985; 313: 709-715
        • Clarke R
        • Leslie D
        • Robinson K
        • Naughten E
        • Cahalane S
        • Fowler B
        • Graham I
        Hyperhomocysteinemia: an independent risk factor for vascular disease.
        N. Engl. J. Med. 1991; 324: 1149-1155
        • Stampfer M.J
        • Malinow M.R
        • Willet W.C
        • Newcomer L.M
        • Upson B
        • Ullman D
        • Tishler P.V
        • Henneken C.H
        A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians.
        J. Am. Med. Assoc. 1992; 268: 877-881
        • Boushey C.J
        • Beresford S.A.A
        • Omen G.S
        • Motulsky A.G
        A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
        J. Am. Med. Assoc. 1995; 274: 1049-1056
        • Refsum H
        • Ueland P.M
        • Nygård O
        • Vollset S.E
        Homocysteine and cardiovascular disease.
        Annu. Rev. Med. 1998; 49: 31-62
        • Mansoor M.A
        • Svardal A.M
        • Ueland P.M
        Determination of in vivo redox status of cysteine, cysteinylglycine, homocysteine and glutathione in human plasma.
        Anal. Biochem. 1992; 200: 218-229
        • Andersson A
        • Lindgren A
        • Hultberg B
        Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction.
        Clin. Chem. 1995; 41: 361-366
        • Ueland P.M
        Homocysteine species as components of plasma redox thiol status.
        Clin. Chem. 1995; 41: 340-342
        • Meister A
        Glutathione metabolism and its selective modification.
        J. Biol. Chem. 1988; 263: 17205-17208
        • Bannai S
        • Tateishi N
        Role of membrane transport in metabolism and function of glutathione in mammals.
        J. Membr. Biol. 1986; 89: 1-8
        • Kretzschmar M
        Regulation of hepatic glutathione metabolism and its role in hepatotoxicity.
        Exp. Toxicol. Pathol. 1996; 48: 439-446
        • Aebi S
        • Assereto R
        • Lauterburg B.H
        High-dose intravenous glutathione in man. Pharmacokinetics and effects on cysteine in plasma and urine.
        Eur. J. Clin. Invest. 1991; 21: 103-110
        • Halliwell B
        • Gutteridge J.M.C
        The antioxidants of human extracellular fluids.
        Arch. Biochem. Biophys. 1990; 280: 1-8
        • Hultberg B
        • Andersson A
        • Arnadottir M
        Reduced, free and total fractions of homocysteine and other thiol compounds in plasma from patients with renal failure.
        Nephron. 1995; 70: 62-67
        • Andersson A
        • Lindgren A
        • Arnadottir M
        • Prytz H
        • Hultberg B
        Thiols as a measure of plasma redox status in healthy subjects and in patients with renal or liver failure.
        Clin. Chem. 1999; 45: 1084-1086
        • Andersson A
        • Isaksson A
        • Brattström L
        • Hultberg B
        Homocysteine and other thiols determined in plasma by HPLC and thiol specific postcolumn derivatization.
        Clin. Chem. 1993; 39: 1590-1597
        • Mansoor M.A
        • Bergmark C
        • Svardal A.M
        • Lönning P.E
        • Ueland P.M
        Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease.
        Arterioscler. Thromb. Vasc. Biol. 1995; 15: 232-240
        • Hultberg B
        • Andersson A
        • Masson P
        • Larson M
        • Tunek A
        Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine.
        Scand. J. Clin. Lab. Invest. 1994; 54: 417-422
        • Guttormsen A.B
        • Svarstad E
        • Ueland P.M
        • Refsum H
        Elimination of homocysteine from plasma on subjects with end-stage renal failure.
        Kidney Int. 1997; 52: 495-502
        • Witzum J.L
        The oxidation hypothesis of atherosclerosis.
        Lancet. 1994; 344: 793-795